Theravance Biopharma, Inc. reported first quarter of 2026 results: revenue $17.7 million.
“Total revenue for the first quarter of 2026 was $17.7 million, consisting entirely of Viatris collaboration revenue.”
Theravance Biopharma, Inc. — fact timeline
Source-grounded facts extracted from Theravance Biopharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Theravance Biopharma, Inc. announced a restructuring with charges of approximately $5 million to $7 million affecting R&D and G&A functions (approximately 50% of the Company’s overall workforce).
“On March 3, 2026, the Company announced an organizational restructuring (the “Restructuring”), which is intended to reduce cost base by approximately 60% (or approximately $70 million) and expected to impact approximately 50% of the Company’s overall workforce. The Restructuring will be implemented over the next two quarters, with the Company expecting to incur approximately $5 million to $7 million in one-time cash severance costs related to the Restructuring.”
Theravance Biopharma, Inc. completed a disposition involving GlaxoSmithKline Intellectual Property Development Limited for $225 million (closed 2025-05-30).
“ompany (“TBPH”) and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered”
Theravance Biopharma, Inc. reported the first quarter of 2024 results: revenue Total revenue for the first quarter of 2024 was $14.5 million, net income Net loss was $11.7 million.
“Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results”
Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution regarding compensation of named executive officers at the 2024-05-08 meeting.
“Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non- Votes Number of Shares Voted 35,205,714 332,345 2,683 3,952,947”
Theravance Biopharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-08 meeting.
“Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified: For Against Abstain Broker Non- Votes Number of Shares Voted 39,257,982 228,078 7,629 N/A”
Theravance Biopharma, Inc. shareholders approved Election of Class I directors: Eran Broshy, James Kelly, Laurie Smaldone Alsup at the 2024-05-08 meeting.
“Proposal One – Based on the following results of voting, the nominees listed below were elected Class I directors to serve as members of the Board until the Company’s Annual General Meeting held in 2026 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non- Votes Eran Broshy 35,316,310 223,797 635 3,952,947 James Kelly 35,265,676 274,631 435 3,952,947 Laurie Smaldone Alsup 35,290,841 240,365 9,536 3,952,947”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.